Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer.
Phase 3positiveZipalertinibPositive
AI Analysis
Summary
Zipalertinib plus chemotherapy met the primary endpoint of progression-free survival in the planned interim analysis of the Phase 3 REZILIENT3 trial for first-line treatment of EGFR Exon 20 Insertion Mutation non-small cell lung cancer. The trial is being developed by Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary endpoint of progression-free survival in planned interim analysis
Importance:8/10
Sentiment:
0.85
OncologyLung CancerPhase 3 DataEGFR MutationPositive Interim Analysis
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 12, 2026 2:08 AM